MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
70.03
+1.50
+2.19%
After Hours: 70.03 0 0.00% 16:10 05/13 EDT
OPEN
68.12
PREV CLOSE
68.53
HIGH
70.38
LOW
66.64
VOLUME
766.25K
TURNOVER
--
52 WEEK HIGH
99.50
52 WEEK LOW
40.00
MARKET CAP
2.68B
P/E (TTM)
-10.5990
1D
5D
1M
3M
1Y
5Y
1D
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON)
TipRanks · 13h ago
'Makary's Time Atop FDA Over, Diamantas Named Acting Commissioner' - Politico
Benzinga · 1d ago
Disc Medicine presents Phase 2 RALLY-MF data for DISC-0974 in myelofibrosis anemia
PUBT · 1d ago
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Barchart · 1d ago
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
PR Newswire · 1d ago
'Trump Approves Plan To Fire FDA Commissioner Marty Makary, Sources Say' - CBS
Benzinga · 2d ago
H.C. Wainwright Sticks to Its Buy Rating for Disc Medicine (IRON)
TipRanks · 2d ago
Disc Medicine joins H.C. Wainwright BioConnect investor conference fireside chat
PUBT · 2d ago
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.